Intraoperative detection of colorectal and pancreatic liver metastases using SGM-101, a fluorescent antibody targeting CEA. (March 2021)

• Record Type: Journal Article
• Authors: Meijer, Ruben P.J.; de Valk, Kim S.; Deken, Marion M.; Boogerd, Leonora S.F.; Hoogstins, Charlotte E.S.; Bhairosingh, Shadhvi S.; Swijnenburg, Rutger-Jan; Bonsing, Bert A.; Framery, Bérénice; Fariña Sarasqueta, Arantza; Putter, Hein; Hilling, Denise E.; Burggraaf, Jacobus; Cailler, Françoise; Mieog, J. Sven D.; Vahrmeijer, Alexander L.
• Is Part Of: European journal of surgical oncology. Volume 47:Supplement Part B (2021)
• Page Start: 667
• Page End: 673
• Publication Date: 2021-03
• Subjects: Fluorescence-guided surgery -- Liver metastases -- Colorectal cancer -- Pancreatic cancer; CEA carcinoembryonic antigen -- EGFR epidermal growth factor receptor -- H&E haematoxylin and eosin -- ICG indocyanine green -- IS intensity score -- NIR near-infrared -- PS percentage score -- TBR tumor-to-background ratio -- TIS total immunostaining score; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2020.10.034
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: Fluorescence-guided surgery can provide surgeons with an imaging tool for real-time intraoperative tumor detection. SGM-101, an anti-CEA antibody labelled with a fluorescent dye, is a tumor-specific imaging agent that can aid in improving detection and complete resection for CEA-positive tumors. In this study, the performance of SGM-101 for the detection of colorectal and pancreatic liver metastases was investigated. Methods: In this open-label, non-randomized, single-arm pilot study, patients were included with liver metastases from colorectal origin and intraoperatively detected liver metastases from pancreatic origin (during planned pancreatic surgery). SGM-101 was administered two to four days before the scheduled surgery as a single intravenous injection. Intraoperative fluorescence imaging was performed using the Quest Spectrum® imaging system. The performance of SGM-101 was assessed by measuring the intraoperative fluorescence signal and comparing this to histopathology. Results: A total of 19 lesions were found in 11 patients, which were all suspected as malignant in white light and subsequent fluorescence inspection. Seventeen lesions were malignant with a mean tumor-to-background ratio of 1.7. The remaining two lesions were false-positives as proven by histology. Conclusion: CEA-targeted fluorescence-guided intraoperative tumor detection with SGM-101 is feasible for the detection of colorectal and pancreatic liver metastases.